États-Unis · Bourse & Finance · The Motley Fool

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

Publié par The Motley Fool · États-Unis il y a 8 h

BioNTech announced that it was stopping a Phase 2 clinical trial for autogene cevumeran, which it was testing as an adjuvant treatment for certain patients with colorectal cancer.…

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

À lire aussi

Bessent warns Zelenskyy to 'be very careful' about claims U.S. is throttling Starlink

What Is Starshield, SpaceX’s Military-Grade Satellite Internet Service Ukraine Relies On?

Everyone’s watching the Elizabeth Holmes documentary ‘You Can See Everything’

The Nuclear Power Shortcut That Could Add Gigawatts to the U.S. Grid

Anthropic commits billions to a 'public benefit fund'

‘Street Fighter’ hits $31M in box office debut as moviegoing jumps 48%

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

Partager

À lire aussi

Bessent warns Zelenskyy to 'be very careful' about claims U.S. is throttling Starlink

What Is Starshield, SpaceX’s Military-Grade Satellite Internet Service Ukraine Relies On?

Everyone’s watching the Elizabeth Holmes documentary ‘You Can See Everything’

The Nuclear Power Shortcut That Could Add Gigawatts to the U.S. Grid

Anthropic commits billions to a 'public benefit fund'

‘Street Fighter’ hits $31M in box office debut as moviegoing jumps 48%